Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.nejm.org › doi › fullVenetoclax–Rituximab in Relapsed or Refractory Chronic ...

    22 de mar. de 2018 · Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017;18:230-240. Crossref

    • John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline...
    • 2018

  2. Imágenes

    • John F Seymour - Alchetron, The Free Social Encyclopedia
    • [Police Chief John F. Seymour] — Calisphere
    • Photos de John Seymour - Babelio.com
    • John Seymour (author) - Alchetron, The Free Social Encyclopedia
    • John Seymour (1474-1536) – kleio.org
    • The Hessian Sack: The Age of Healing by John Seymour

    Ver todo

  3. scholar.google.com › citations‪John F Seymour‬ - ‪Google Scholar‬

    Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. KR Carson, AM Evens,...

  4. en.wikipedia.org › wiki › John_Seymour_(CaliforniaJohn Seymour (California politician) - Wikipedia

    John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States senator from California from 1991 to 1992.

  5. www.nature.com › articles › s41408/024/01001-1Update on the management of relapsed/refractory chronic ...

    21 de feb. de 2024 · John F. Seymour. Blood Cancer Journal 14, Article number: 33 ( 2024 ) Cite this article. 11 Altmetric. Metrics. Abstract. Chronic lymphocytic leukemia (CLL) predominantly affects older...

  6. ashpublications.org › blood › articleDegraders upgraded: the rise of PROTACs in hematological ...

    28 de mar. de 2024 · Casan and Seymour provide a state-of-the-art review of proteolysis-targeting chimeras (PROTACs), the leading class of targeted protein degradation agents.

  7. pubmed.ncbi.nlm.nih.gov › 32358081Association of early disease progression and very poor ...

    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

  8. pubmed.ncbi.nlm.nih.gov › 34102145Should Undetectable Minimal Residual Disease Be the Goal of ...

    This review discusses available methods of minimal residual disease measurement. It summarizes minimal residual disease data from pivotal clinical trials and discusses potential implications for future studies and minimal residual disease-based clinical strategies.